Edit
Minerva Neurosciences
http://www.minervaneurosciences.com/?portfolioCats=34,23,29,35,22,24,30,25,28,31#new_tabLast activity: 03.06.2024
Active
Dedicated to transforming the lives of patients with central nervous system diseases through innovative solutions.
Location: United States, Massachusetts, Waltham
Employees: 11-50
Founded date: 2007
Investors 1
| Date | Name | Website |
| - | Vivo Capit... | vivocapita... |
Mentions in press and media 13
| Date | Title | Description |
| 03.06.2024 | Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors | PITTSBURGH, June 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that as part of its ongoing Board refreshment efforts, Rogerio Vivaldi Coelho, M.D., has been appointed as the newest member ... |
| 10.03.2024 | Blockbuster BeiGene Cancer Drug Adds Another FDA Approval | A BeiGene drug already used to treat several types of blood cancer now has an additional FDA approval as a treatment for follicular lymphoma. The regulatory decision makes the BeiGene drug the first in its class for treating this type of ca... |
| 09.08.2022 | Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates | WALTHAM, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported... |
| 04.05.2022 | Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates | WALTHAM, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported ... |
| 28.02.2022 | Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin | WALTHAM, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announce... |
| 05.01.2022 | Minerva Neurosciences : Corporate Presentation at LifeSci Partners Corporate Access Event | Corporate Presentation January 2022 Forward-Looking Statement Safe-Harbor Forward-Looking Safe Harbor Statement This presentation contains forward-looking statements. Forward-looking statements are statements that are not historical facts, ... |
| 08.11.2021 | Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates | Company to Host Conference Call Today at 8:30 a.m. ET WALTHAM, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat ... |
| 08.11.2021 | Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates | Company to Host Conference Call Today at 8:30 a.m. ET WALTHAM, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat ... |
| 01.11.2021 | Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8 | WALTHAM, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announce... |
| 11.10.2021 | Minerva Neurosciences Announces Promotion of Geoff Race to President | Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Request to FDA WALTHAM, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutic... |
Show more